HER2 testing in colorectal cancer looks for abnormal ERBB2/HER2 activation, usually through strong protein expression and/or gene amplification. It is most relevant in metastatic colorectal cancer that is RAS wild type, where a HER2-positive result can open a targeted-treatment pathway after standard chemotherapy. Colorectal HER2 is not interpreted with exactly the same rules used in breast or gastric cancer. Laboratories may use immunohistochemistry, in-situ hybridization, and next-generation sequencing, often with colorectal-specific criteria that emphasize strong membranous staining in a substantial proportion of tumor cells or clear ERBB2 amplification. HER2 amplification can also be a mechanism of resistance to anti-EGFR therapy. A negative result does not change the importance of testing RAS, BRAF, and MSI/dMMR, while a positive result should be read alongside RAS status, prior therapies, assay method, and current drug-label criteria. The report is therefore a treatment-selection tool, not a general blood tumor marker.
- Colon-cancer HER2 testing is performed on tumor tissue or validated molecular material; it is not the serum HER2 test used in some other settings.
- HER2-positive metastatic colorectal cancer is uncommon, roughly a few percent overall and enriched in RAS/BRAF wild-type disease.
- Protein overexpression and ERBB2 amplification are related but not identical; IHC, ISH, and NGS may be used together.
- The FDA-approved tucatinib-plus-trastuzumab indication requires RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer after specified chemotherapy.
- HER2 scoring should use colorectal-appropriate criteria rather than assuming breast or gastric thresholds.
Table of Contents
- What HER2 means in colorectal cancer
- IHC, ISH, and NGS testing methods
- How to interpret HER2-positive, equivocal, and negative results
- HER2 and resistance to anti-EGFR treatment
- HER2-targeted treatment implications
- Limitations and reasons results can disagree
- Practical next steps after HER2 testing
What HER2 means in colorectal cancer
HER2 is a receptor tyrosine kinase encoded by ERBB2. When the gene is amplified, tumor cells can produce excessive HER2 protein and depend on that signaling for growth. This is a distinct molecular subgroup of colorectal cancer and is different from simply having normal HER2 expression.
HER2 amplification is more common in RAS/BRAF wild-type metastatic disease than in unselected colorectal cancer. It can coexist with other alterations, so a positive HER2 result does not erase the rest of the molecular profile. In particular, RAS status remains central because the major U.S. tucatinib/trastuzumab indication specifies RAS wild-type disease.
IHC, ISH, and NGS testing methods
Immunohistochemistry measures HER2 protein on the tumor-cell membrane and reports intensity and distribution. In-situ hybridization evaluates ERBB2 gene copy number or the ERBB2-to-chromosome-17 signal relationship. Next-generation sequencing can detect ERBB2 amplification and other coexisting genomic changes.
Concordance is often good in clearly amplified tumors, but borderline cases can differ by platform. A small biopsy with heterogeneous staining may underrepresent a positive clone. For treatment decisions, the report should identify the exact assay and criteria. If NGS reports low-level amplification without confirmatory protein expression, or IHC is equivocal, additional testing may be appropriate before assigning HER2-targeted therapy.
How to interpret HER2-positive, equivocal, and negative results
A strongly positive colorectal HER2 result usually means convincing membranous overexpression in a sufficiently large fraction of tumor cells and/or clear ERBB2 amplification. Equivocal results occupy a gray zone where another method can clarify whether true oncogenic amplification is present. Negative means the assay did not meet its positivity threshold; it does not mean ERBB2 biology can never evolve later.
Because published trials have used specific eligibility definitions, treatment qualification should be matched to the regimen rather than inferred from a generic “HER2+” label. The safest report includes IHC score, percentage of positive cells, ISH result when performed, NGS copy-number call, and RAS status.
HER2 and resistance to anti-EGFR treatment
EGFR signaling and HER2 signaling connect within the same receptor network. ERBB2 amplification can provide an alternative growth signal when EGFR is blocked, which helps explain why some RAS wild-type HER2-amplified tumors respond poorly to cetuximab or panitumumab. This relationship is clinically useful but not absolute: treatment history, tumor sidedness, amplification level, and co-alterations also matter.
HER2 testing is therefore often most informative before later-line targeted therapy and when anti-EGFR resistance is being evaluated. Liquid-biopsy profiling can sometimes detect acquired ERBB2 amplification after prior anti-EGFR exposure, but tissue remains important when confirmation is needed.
HER2-targeted treatment implications
In the United States, tucatinib plus trastuzumab received accelerated approval in 2023 for adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The approval was based on the MOUNTAINEER study, which demonstrated clinically meaningful responses in this selected population.
Other HER2-directed strategies, including antibody-drug conjugates and dual-antibody combinations, have shown activity and may be available through guidelines, other jurisdictions, or clinical trials. Eligibility details change, so the oncologist should match the exact HER2 definition and prior-treatment requirements to the current label.
Limitations and reasons results can disagree
No biomarker works in isolation. A technically accurate result can still be clinically misleading if it is applied to the wrong cancer type, disease stage, specimen, or treatment question. Cutoffs may also differ by assay, drug label, guideline, and country. For that reason, the laboratory’s own interpretive criteria and the treating team’s current guideline should take priority over a generic internet threshold.
Tumors are heterogeneous, meaning different areas can carry different alterations or levels of protein expression. A small biopsy may miss a positive clone, while a blood-based assay can miss disease that sheds little DNA into the circulation. Conversely, a detectable alteration may be real but not be the main driver of the current disease. Pre-analytic issues such as delayed fixation, decalcification, low tumor content, recent transfusion, or poor plasma handling can also affect some assays.
The safest interpretation separates three questions: analytical validity—did the assay measure what it claims to measure; clinical validity—does the result correlate with the cancer feature of interest; and clinical utility—does acting on the result improve a meaningful decision for this patient. A result can be strong in one category and limited in another.
Practical next steps after HER2 testing
A biomarker result should be read beside the pathology report, stage, imaging, treatment history, and the exact specimen tested. A useful question for the oncology team is not simply “is this positive?” but “what decision does this result change now?” That keeps the result tied to a concrete action such as confirming a diagnosis, choosing a drug, deciding whether hereditary evaluation is needed, or setting a surveillance plan.
If a result seems inconsistent with the clinical picture, ask whether the sample had enough viable tumor, whether the method covered the relevant alteration, and whether a newer metastatic or recurrent specimen would be more representative. Repeating a test is most useful when there is a specific reason to think the original specimen was inadequate, old, or biologically different from the disease being treated today.
Patients should also keep a copy of the complete molecular or pathology report, not only a portal summary. The full report usually lists the method, specimen, tumor percentage, assay limitations, exact variant or staining score, and interpretive comments. Those details matter when seeking a second opinion, transferring care, or checking eligibility for a targeted therapy or clinical trial.
One practical way to avoid overreading HER2 Test for Colon Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Colon Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Colon Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
Finally, biomarker testing works best as part of multidisciplinary care. Pathologists judge specimen quality and assay interpretation; medical oncologists connect the finding to treatment; surgeons and gastroenterologists provide disease context; genetic counselors address possible inherited risk when appropriate. Patients do not need to master every technical detail, but they benefit from knowing the purpose of the test, the exact result, what uncertainty remains, and what concrete decision follows. Those four questions turn a complex biomarker report into a usable plan.
One practical way to avoid overreading HER2 Test for Colon Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Colon Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Colon Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
Finally, biomarker testing works best as part of multidisciplinary care. Pathologists judge specimen quality and assay interpretation; medical oncologists connect the finding to treatment; surgeons and gastroenterologists provide disease context; genetic counselors address possible inherited risk when appropriate. Patients do not need to master every technical detail, but they benefit from knowing the purpose of the test, the exact result, what uncertainty remains, and what concrete decision follows. Those four questions turn a complex biomarker report into a usable plan.
One practical way to avoid overreading HER2 Test for Colon Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Colon Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Colon Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
Finally, biomarker testing works best as part of multidisciplinary care. Pathologists judge specimen quality and assay interpretation; medical oncologists connect the finding to treatment; surgeons and gastroenterologists provide disease context; genetic counselors address possible inherited risk when appropriate. Patients do not need to master every technical detail, but they benefit from knowing the purpose of the test, the exact result, what uncertainty remains, and what concrete decision follows. Those four questions turn a complex biomarker report into a usable plan.
One practical way to avoid overreading HER2 Test for Colon Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Colon Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Colon Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
Finally, biomarker testing works best as part of multidisciplinary care. Pathologists judge specimen quality and assay interpretation; medical oncologists connect the finding to treatment; surgeons and gastroenterologists provide disease context; genetic counselors address possible inherited risk when appropriate. Patients do not need to master every technical detail, but they benefit from knowing the purpose of the test, the exact result, what uncertainty remains, and what concrete decision follows. Those four questions turn a complex biomarker report into a usable plan.
References
- SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022) 2023 (Guideline)
- Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology 2017 (Guideline)
- HER2-targeted therapy in colorectal cancer: a comprehensive review 2025 (Review)
- FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer 2023 (Official)
- Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer 2025 (Guideline)
Disclaimer
This article explains biomarker testing for educational purposes and is not a diagnosis or treatment plan. Cancer testing and treatment should be interpreted by the oncology and pathology teams using the complete medical record, current guidelines, and the specific laboratory method. Seek prompt medical care for new or rapidly worsening symptoms rather than relying on a biomarker result alone.
